Navigation Links
Onyx Pharmaceuticals Acquires Option to License Novel Highly Specific JAK2 Inhibitors From S*BIO
Date:1/6/2009

treatment of advanced kidney cancer and liver cancer. Additionally, Nexavar is being investigated in several ongoing trials in non-small cell lung cancer, melanoma, breast cancer, and other cancers. For more information about Onyx, visit the company's website at http://www.onyx-pharm.com.

About S*BIO Pte Ltd

S*BIO is a privately-held biotechnology company focused on the research and clinical development of novel targeted small molecule drugs for the treatment of cancer. The company's lead programs focus on histone deacetylases (HDAC) and kinases. S*BIO has an established R&D infrastructure that is complemented by a clinical development team. In addition, S*BIO has links with a network of medical oncologists in Asia Pacific. More information about S*BIO can be found at www.sbio.com.

Forward-Looking Statements

This news release contains "forward-looking statements" within the meaning of the federal securities laws. These forward-looking statements include, without limitation, statements regarding potential clinical applications for SB1518 and SB1578, the potential for their development and commercialization, the clinical development, regulatory processes, and commercialization efforts related to Nexavar and Onyx's expectation that it will be profitable on a non-GAAP basis for the 2008 fiscal year. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Reference should be made to Onyx's Annual Report on Form 10-K for the year ended December 31, 2007, filed with the Securities and Exchange Commission under the heading "Risk Factors" and Onyx's Quarterly Reports on Form 10-Q for a more detailed description of such factors. Readers are cautioned not to place undue reliance on forward-looking statements
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Akrimax Pharmaceuticals Announces Manufacturing Partnership
2. Prism Pharmaceuticals to Present at the 27th Annual J.P. Morgan Healthcare Conference
3. Prism Pharmaceuticals Receives FDA Approval of NEXTERONE(R) for Life-Threatening Ventricular Fibrillation and Ventricular Tachycardia
4. AUDIO from Medialink and Solvay Pharmaceuticals: New Initiative Urges Women to Address Mens Health this New Year
5. Indevus Pharmaceuticals Announces Definitive Merger Agreement With Endo Pharmaceuticals
6. Endo Pharmaceuticals to Acquire Indevus Pharmaceuticals
7. Alexion Pharmaceuticals and PDL BioPharma Resolve Patent Dispute
8. Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
9. Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
10. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
11. Cognition Pharmaceuticals Announces Positive Memory Results for Phase II Trial of C105 in Multiple Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Francisco, September 15, 2014A prospective study that compared ... patients with bone metastases demonstrates that single fraction ... multiple fraction radiation therapy (MFRT) when pain, function ... research presented today at the American Society for ... study indicates that improvements in patients, pain, function ...
(Date:9/16/2014)... 16, 2014 Fresh shiitake mushrooms ... and potassium. They are second-most consumed mushroom worldwide, ... their healing and health properties. , In addition ... can stimulate and strengthen the immune system and ... polycharrides, including beta glucans . These medicinal ...
(Date:9/16/2014)... 16, 2014 Synergy Research Group has ... gives the best detail and analysis of the state ... a variety of sources, including Ministry of Health in ... will give readers actionable intelligence on clinical trials in ... relied on by the local and international life science ...
(Date:9/16/2014)... Wholelifeinsurancecompanies.org has released a new blog post ... bad heart condition. , Clients who have a bad ... they compare quotes. Most agencies will insure applicants who ... actual and past medical condition. , If someone ... in the past, his or her chances of finding ...
(Date:9/16/2014)... had children (parous women) appear to have an ... the subtype that carries a higher mortality rate ... ancestry. A similar relationship was found for ... and increased risk of estrogen receptor-negative and triple-negative ... who had never breastfed. These findings, published in ...
Breaking Medicine News(10 mins):Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 2Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 3Health News:Single fraction RT as effective as multiple fraction RT for bone metastases 4Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 2Health News:As Fall Schedules Settle In, Block Stress-Related Illness with Your Own Shiitake Mushroom Log Kit from Lost Creek Mushroom Farm 3Health News:Synergy Research Group Debuts Ukraine Orange Paper 2Health News:No Exam Life Insurance for Clients Who Have a Bad Heart Condition! 2Health News:Lactation linked to reduced estrogen receptor-negative, triple-negative breast cancer risk 2
... The Food and Drug Administration (FDA) has awarded ... three-year, $1 million Orphan Products Development grant to ... the skin or internal organs., The unique, interdisciplinary, ... Beth Drolet, M.D., professor of dermatology and pediatrics, ...
... Governors Gene Therapeutics Research Institute at Cedars-Sinai Medical Center ... possible to sustain therapeutic gene expression in the central ... the presence of an anti-viral immune response mechanism that ... demonstrated in an animal model that the delivery system ...
... to be a multi-stage, multi-mechanism process by animal and ... Helicobacter pylori (H pylori) in the formation of gastric ... on November 7 in the World Journal of Gastroenterology ... H pylori on gastric cancer. , Gap junctions ...
... researchers say , THURSDAY, Oct. 25 (HealthDay News) -- ... can lessen cardiac injuries after heart attack and boost patient ... study in this week,s issue of The Lancet , ... muscle (infarct) and lessened what,s known as "reperfusion injuries," caused ...
... AMICAS, Inc (Nasdaq: AMCS ),announces the following Webcast: ... Webcast, When: November 1, 2007 @ 8:30 AM ET, ... the Internet -- Simply log on to the web at the ... Lisa Gould of AMICAS, Inc, 617-779-7892. If you are ...
... can search, sort, and compare more than 500 health ... plans on quality ... World Report and the,National Committee for Quality Assurance (NCQA) today ... ranking of U.S. health,maintenance organizations and point-of-service plans. Coinciding with ...
Cached Medicine News:Health News:Medical College of Wisconsin receives FDA grant 2Health News:Medical College of Wisconsin receives FDA grant 3Health News:Helicobacter pylori inhibits intercellular communication of cultured gastric cells 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 2Health News:U.S.News & World Report, NCQA Release Annual Rankings for 'America's Best Health Plans' 3
(Date:9/16/2014)... 16, 2014  Formex, LLC ("Formex"), a ... Mr. Greg Weilersbacher joined Formex as Director of ... Greg Weilersbacher has over ... expertise in Quality Assurance, Facility Validation, GMP ... brings to Formex a diverse wealth of ...
(Date:9/16/2014)... RICHMOND, Va. , Sept. 16, 2014 /PRNewswire-USNewswire/ ... (NAMCP) Medical Directors Institute has simultaneously released the ... the NAMCP Medical Diagnostics Dossier Template © , ... dossier template formats for either medical devices or ... unique aspects of each of these technology types ...
(Date:9/16/2014)... Northwest Biotherapeutics (NASDAQ: NWBO ) ... therapies for solid tumor cancers, announced today that its ... as a "Promising Innovative Medicine" (PIM) under the new ... UK in April 2014.  A PIM is the first ... under the EAMS.  The PIM designation ...
Breaking Medicine Technology:Greg Weilersbacher Joins Formex, LLC As Director of Quality Assurance and Quality Control 2NAMCP Medical Directors Institute releases NAMCP Medical Technologies and Diagnostics Dossier Templates to provide model approach for medical devices or diagnostics 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 2NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 3NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 4NW BIO'S CANCER VACCINE IS THE FIRST DRUG TO BE DESIGNATED BY UK AUTHORITIES AS A "PROMISING INNOVATIVE MEDICINE" (PIM) 5
... Sept. 20, 2011 TheraVasc ( www.theravasc.com ) announced the ... drug, TV1001, to diabetic patients. The trial included 12 diabetic ... oral formulations of TV1001, an enteric coated and a non-enteric ... drug.  Based on prior studies conducted in animals, the circulating ...
... American Medical Systems (AMS), a leading provider of world-class ... today announced the launch of a new consumer friendly website ... partners learn how penile prosthetic implants can restore sexual function ... the popularity of ED medications, these drugs fail to resolve ...
Cached Medicine Technology:TheraVasc Releases Phase I Trial Data Demonstrating Safety of Drug in Diabetic Patients 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 2New Website Provides Comprehensive Resource to Anyone With Erectile Dysfunction 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: